Surveys of hospital pharmacists
|
|
|
- Peregrine Hill
- 10 years ago
- Views:
Transcription
1 : practice site versus a class 1000 cleanroom MARK THOMAS, MICHAEL D. SANBORN, AND RICK COULDRY Surveys of hospital pharmacists suggest that, while guidelines regarding i.v. preparations have existed for many years, most pharmacies have been slow to adopt recommendations regarding the compounding environment, training of personnel, and quality assurance. National surveys conducted by the American Society of Health-System s (ASHP) in 1995 and 2002 failed to show significant changes in the sterile compounding practices of hospital pharmacists. 1,2 Requirements that mandate procedures and environmental safeguards, including the use of a cleanroom environment for the preparation of sterile admixtures in hospitals, have been published in chapter 797 in the United States Pharmacopeia (USP). 3 USP chapter 797 is also being incorporated into the Joint Commission on Accreditation of Healthcare Organization s survey process and will likely be adopted by many state boards of pharmacy. Most pharmacies are planning for or completing the renovations necessary for such an environment, and the costs associated with these changes are significant. The importance of environmental hygiene for the processing of sterile admixtures has been stressed for a Purpose. The contamination rates associated with the preparation of medium-risk i.v. admixtures in a traditional practice site and in a class 1000 cleanroom were compared. Methods. Simulated product media fills served as the samples. Each investigator, a pharmacist and a pharmacy technician, prepared 500 vials and 500 small-volume parenteral (SVP) bags in five separate runs at a traditional practice site and in a cleanroom. United States Pharmacopeia chapter 797 medium-risk compounding procedures were followed, and strict adherence to aseptic technique was employed. Singlestrength tryptic soy broth was substituted for the drug and diluent in the admixtures. Positive and negative controls were also prepared and stored for the duration of the study. The pharmacist and technician prepared a total of 4057 samples: 2027 samples (1014 vials and 1013 SVP bags) were prepared in a class 1000 cleanroom, and 2030 (1014 vials and 1016 SVP bags) were prepared at a traditional practice site. Results. Contamination rates did not significantly differ between the traditional practice site (0.296%) and the cleanroom environment (0.344%) (p = ). A significant difference in the number of contaminated samples was found between the two investigators (2 of 2057 were contaminated by the pharmacist and 11 of 2000 were contaminated by the technician) (p = 12). Contamination rates by the pharmacist (p = ) and technician (p = ) did not significantly differ between sites. Conclusion. The most important variable affecting microbial contamination of admixtures was the aseptic technique of personnel, not the environment in which the drugs were compounded. Index terms: Additives; Aseptic areas; Compounding; Contamination; Control, quality; Injections; Personnel, pharmacy; s Am J Health-Syst Pharm. 2005; 62: number of years. A study evaluating the effect of laminar airflow (LAF) and cleanroom garb revealed that the rate of contamination of admixtures compounded in LAF hoods (2 of 650 total samples were contaminated) was significantly less than that for those compounded on a clean tabletop (9 of 650 samples were contaminated) (p = 5), regardless of the operator s dress. 4 The study also found that cleanroom garb had no apparent effect on the outcome of contamination rates of admixtures, regardless of the environment in which the admixture was prepared. MARK THOMAS, M.S., B.S., is Director of Pharmacy, Cook Children s Medical Center, Fort Worth, TX. MICHAEL D. SANBORN, M.S., B.S., FASHP, is System Director of Pharmacy Services, Baylor University Medical Center, Dallas, TX. RICK COULDRY, M.S., B.S., is Director of Pharmacy, Department of Pharmacy, University of Kansas Hospital, Kansas City. Address correspondence to Mr. Sanborn at Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX ([email protected]). Copyright 2005, American Society of Health-System s, Inc. All rights reserved /05/ $ DOI /ajhp Am J Health-Syst Pharm Vol 62 v 15, 2005
2 Another study compared the contamination rates of admixtures prepared in the LAF hood and admixtures prepared on the nursing unit by nurses. 5 The rate of contamination was higher in admixtures prepared on the nursing unit versus those prepared in the LAF hood (10.9% versus 5.5%, respectively). Touch contamination played a major role in the contaminated samples, demonstrating the importance of strict aseptic technique. I.V. admixture contamination rates reported in the literature range from 0% to 14.5% (Table 1) Studies that tested for contamination using simulated product media fills had the lowest reported contamination rates, suggesting a lower frequency of adventitious contamination with this method. 7-11,18,19 Further, Trissel et al. s 18,19 two independent benchmark contamination rate studies demonstrated a much higher contamination rate in the cleanroom versus the noncleanroom setting (5.2% versus <0.1%, respectively). To date, no published studies have directly compared the contamination rates of cleanrooms with traditional compounding environments. The purpose of this study was to compare the contamination rates of medium-risk compounding of simulated product media fills prepared under traditional practice conditions and under class 1000 cleanroom conditions. Methods The compounding process used in this study was designed to simulate chapter 797 medium-risk compounding using batch preparation of an i.v. admixture that required reconstitution of the drug and subsequent transfer to an i.v. piggyback. Sample preparation. Simulated product media fills served as the samples. Each investigator prepared admixtures using aseptic transfer. Singlestrength tryptic soy broth a (TSB) was substituted for each component of the admixture (drug and diluent). The diluent consisted of 1000 ml of single-strength TSB in a 1-L polyvinyl chloride (PVC) bag simulating a 1-L bag of sterile water for injection. Empty sterilized 30-mL vials were used to simulate the drug component. Thirty milliliters of TSB was transferred into these empty vials from the diluent bag, the vials were shaken to simulate reconstitution, and the contents were transferred from the vial into the final container, an empty 50-mL small-volumeparenteral (SVP) bag. The TSB was transferred, using aseptic technique, simulating the actual admixture production process. Turbidity was measured by direct examination of the simulated product after incubation. Samples were prepared following identical preparation procedures at two different sites. At the first site, media fills were prepared under traditional practice conditions, similar to those described in the ASHP National Survey of Quality Assurance Activities for Pharmacy-Prepared Table 1. Summary of Studies Evaluating I.V. Contamination Rates Using Various Sampling Methods and Environments Ref. n Sampling Method(s) Membrane filtration, USP Membrane filtration, USP Addi-Chek filtration a (modified) Membrane filtration Membrane filtration b Membrane filtration b Membrane filtration Laminar- Airflow Workbench? Contamination Rate (%) a Millipore Corp., Bedford, MA. b 0.5-μm inline filter. Am J Health-Syst Pharm Vol 62 v 15,
3 Sterile Products in Hospitals. 20 The pharmacy included a limited-access room (91 sq ft) dedicated to sterile admixture production, where pharmacy personnel prepared sterile admixtures without gloves, low-shed garments, masks, hair covers, or shoe covers. The limited-access room had one doorless entrance, no anteroom or product preparation room, stock shelves with i.v. fluids and drugs, and an unfiltered air supply. The room held two freestanding, inspected, and certified class 100 LAF hoods, a vertical LAF hood for compounding antineoplastics, and a horizontal LAF hood for compounding SVPs and large-volume parenterals. All samples at this site were prepared in the same class 100 horizontal LAF hood (EdgeGARD, Baker Co., Sanford, MA). Figure 1 depicts the floor diagram of the pharmacy area. The second compounding site employed an International Standards Organization (ISO) class 6 (class 1000) cleanroom (288 sq ft) with an entrance from an ISO class 7 gowning room and an exit to an ISO class 7 product preparation room. Access to the gowning room required passing through an ISO class 8 anteroom. The cleanroom had positive pressure ( 5 in of water) and was supplied with high-efficiency particulate air (HEPA) filtered air (39.6 air exchanges/hr), with particle-free walls, floors, and ceilings. The compounding equipment consisted of two freestanding, inspected, and certified vertical LAF hoods and one metal frame workbench. Before entering the cleanroom, pharmacy personnel donned a low-shed gown over surgical scrubs, sterile gloves (double gloved), a hair cover, a mask, and shoe coverings. All samples in this site were prepared in the same class 100 vertical LAF hood (Nuaire, Plymouth, MN). Figure 2 outlines the floor diagram of the cleanroom and surrounding areas. Aseptic technique, an important component of this study, was strictly Figure 1. practice-site floor diagram. LAF = laminar airflow. LAF Hood Work Area I.V. Room Computer Room followed at both sites. Two investigators (a pharmacy student who had five years of experience in preparing i.v. admixtures as a pharmacy technician and a pharmacist with two years of experience as a pharmacist in charge of an i.v. room and who had trained numerous personnel in aseptic technique) prepared the samples at each site. Both investigators had previously been evaluated for and proven competent in aseptic technique in both horizontal and vertical LAF hood environments via didactic training and visual observation. Each investigator prepared at least 500 vials and 500 SVP bags in 5 separate runs at the traditional practice and cleanroom sites. At least 100 vials and 100 bags were prepared per run, meaning that at least 2000 samples were prepared within 10 runs per site. Aseptic transfer. The aseptic transfer procedures used at both sites were identical, allowing for differences in LAF hood configurations (horizontal versus vertical). Differences occurred only during pretransfer and posttransfer procedures, due to special requirements dictated by the policies and procedures of the cleanroom site, which included donning cleanroom garments, spraying equipment with 70% isopropyl alcohol before taking it into the cleanroom, and labeling the SVP bags outside the cleanroom in the product preparation room. When using the LAF hoods, aseptic transfer procedures were identical. The investigators assembled all necessary equipment before entering the hoods. Investigators at the traditional site washed their hands for two to three minutes using a 4% chlorhexidine antimicrobial soap and dried their hands with a paper towel. Investigators at the cleanroom site used a surgical scrub brush with parachlorometaxylenol for the same period of time and dried their hands with a motorized air hand drier. The investigators rewashed their hands upon returning anytime they left the compounding area. Each bag was numbered in the order in which it was prepared. At the traditional practice site, the bags were removed from the LAF hood and labeled while still in the i.v. room. In the cleanroom, labels were affixed to the bags in the product preparation room adjacent to but separate from the cleanroom. Horizontal LAF Hood 2388 Am J Health-Syst Pharm Vol 62 v 15, 2005
4 Figure 2. Cleanroom floor diagram. LAF = laminar airflow. Product Storage LAF Hood Filling Chamber The samples from each site were stored in the same environment and incubated for 14 days at 35 C. Samples were visually inspected for turbidity on day 7 by the principal investigator and on day 14 by a microbiologist. The microbiologist was not given any information about where the samples were prepared or who prepared them. She had access only to the lot and vial or bag numbers and reported the results using those numbers. When contamination was evident, the organisms were identified by genus by the microbiologist, and the integrity of the container was examined. Preparation of controls. Positive controls were used throughout the study to determine if the admixtures were capable of supporting growth at minimal exposure. Twenty-four vials and SVP bags were inoculated in a class 100 LAF hood with low concentrations (growth rates in the logarithmic phase, bacteria/ml) of either Staphylococcus epidermidis or Escherichia coli. The organisms in these controls were identified, after incubation, by the microbiologist to verify that turbidity was attributable to the inoculum. Negative controls (50 SVP bags and five vials) were used to validate the use of aseptic technique. The negative-control SVP bags were prepared by aseptically transferring 20 ml of TSB from one of the diluent bags inside an LAF LAF Hood Gowning Room Anteroom hood and then incubated for 14 days at 35 C. Any turbid bags were discarded. nturbid vials from the first run were used as negative controls. Five negative-control bags were simultaneously incubated with each of the manipulated product simulation runs. The five negative control vials were kept inside the incubator during the study. Background microbial load. Viable particle-air samples were taken to determine the background microbial load of the LAF hoods and the immediate surrounding environment. At least three air samples were collected inside the LAF hoods and the rooms containing the LAF hoods using the Biotest RCS Centrifugal Air Sampler (Biotest Diagnostics Corp., Fairfield, NJ). This air sampler quantifies the number of microbial colonyforming units (CFUs) per volume of air. The number of CFUs were counted, averaged, and reported using the following equation: CFUs/m 3 = (colonies on agar strip 25)/sampling time (min) Statistical analyses were conducted using a two-tailed Fisher s exact test. This test was selected because of the low frequency of contamination expected at both sites. Results The number of samples prepared and the number of contaminated samples are listed by investigator in Table 2. At the traditional practice site, 6 of 2027 samples were contaminated, yielding a contamination rate of 0.296%. Of the 2030 samples prepared in the cleanroom, 7 were contaminated (0.344%). A breakdown of contaminated samples by run, investigator, site, and contaminant is displayed in Table 3. Of the positive samples, three were vials and 10 were SVP bags. Fourteen of the 20 runs had no positive results, 3 runs had 1 positive result, 2 runs had 2, and 1 run had 6 positive results. All positive samples were turbid on days 7 and 14. All 24 of the inoculated positive controls became turbid, indicating contamination. In each case the organism identified by the microbiologist was identical to the one with which the sample was inoculated. ne of the negative controls developed turbidity. Air sampling revealed no viable organisms in either LAF hood. There was an average of 100 CFUs/m 3 in the traditional practice site s surrounding environment and 13 CFUs/m 3 in that of the cleanroom. Table 4 summarizes the statistical outcomes of this study by dependent and independent variables. Discussion Sampling method. This study used simulated product media fills with positive and negative controls as the sampling method. Limitations exist with other available sampling methods. For example, the direct transfer method requires the destruction of the admixture, therefore making large quantity sampling impractical. End-product methods require an additional manipulation, not a natural part of the admixture preparation process, to generate samples. This additional step invites adventitious contamination, leading to falsely high contamination rates. In this study, the results were read Am J Health-Syst Pharm Vol 62 v 15,
5 Table 2. Observed Contamination Rates for and Cleanroom Environments Site Cleanroom a SVP = small-volume parenteral. Personnel Vials 2/500 0/514 1/499 0/515. Contaminated Samples/. Samples Tested SVP Bags a Total Samples Total per Site a 3/500 5/1000 6/2027 1/513 1/1027 5/501 6/1000 7/2030 1/515 1/1030 Table 3. Contaminated Samples Classified by Run, Investigator, and Site Run Investigator Site Bag or Vial Cleanroom Cleanroom Organism Corynebacterium species Bacillus species Corynebacterium species Bacillus species Table 4. Statistical Outcomes of Study by Dependent and Independent Variables Dependent Variables Vial, SVP bag a Fisher s exact test. b SVP = small-volume parenteral, NA = not applicable. Independent Variables Cleanroom, vial site, vial Cleanroom, SVP bag b site, SVP bag, vial, SVP bag, vial, SVP bag, vial, SVP bag, vial, SVP bag, vial, SVP bag, cleanroom, traditional site, vial, SVP bag Cleanroom, traditional site, vial, SVP bag p a NA directly from the final container in simulated product media fills. The operator was the only person who had an opportunity to introduce contamination into the sample. The use of this method removed adventitious contamination as a variable affecting the study, produced a large number of samples, and permitted a study of process rather than product. Media fills were prepared from components used in actual practice to authenticate this study. For example, PVC bags were used instead of glass bottles to simulate the diluent component because bags of sterile water for injection are normally used in the admixture process and there are subtle differences in the manipulation of bags versus bottles. Of the 75 1-L bags prepared for this study, 64 were used. ne of the 75 bags became turbid after incubation, indicating that all of the study samples 2390 Am J Health-Syst Pharm Vol 62 v 15, 2005
6 were prepared with sterile TSB. The remaining components (vials, SVP bags, multiple additive sets, syringes, and needles) are commonly used in the normal admixture process and are available from the manufacturers presterilized. All 24 positive controls became turbid. In each case, the organism identified after incubation was the same organism originally inoculated, supporting the validity of the sampling methodology. The positive controls demonstrated the ability of the media to support a low concentration of microbial contamination throughout the entire study period. The number of samples prepared in this study, 4057 vials and bags, is almost triple the total number of samples prepared in previous contamination studies The number of samples prepared is an important consideration in contamination studies measuring statistical significance, which should have a sample size large enough to yield a high probability of detecting low incidences of contamination. 21 Runs of 100 sample pairs (100 vials and 100 bags) were chosen because this number is a practical simulation of worstcase conditions within a pharmacy, representing the longest period of time that one would prepare admixtures without a break. The runs took hours to prepare. The two investigators were aware of the study and that the products they were preparing were being monitored. Any investigator bias that may have been introduced was addressed as part of the study design. The study was designed to compare preparation environments (traditional practice versus cleanroom). In addition, the length of the runs was designed to challenge the investigator s physical abilities and aseptic technique. The results of this study were analyzed by sample type, vial and SVP bag, and then combined into a total sample. Although the containers differ physically, no significant difference in the contamination rates between the two sample sets (vials versus SVP bags) was found (p = 92). Study findings. This study found no significant difference in the contamination rates of simulated product media fills prepared at the traditional practice site versus those prepared in the cleanroom (p = ). However, the technician, with five years of experience using aseptic technique, contaminated 11 samples in both areas, while the pharmacist contaminated 2 in both areas (p = 12). This supports the argument that operator technique is an important factor in the control of microbial contamination. The importance of good aseptic technique, regardless of the environment, is further illustrated when comparing each investigator s contamination rate by site. significant difference was found in the technician s or pharmacist s contamination rate between the two sites (p = for each investigator). It is reasonable to assume that reducing the microbial load of the surrounding environment would decrease the potential for contamination due to viable airborne particulate matter. The results of this study indicate that this assumption is not accurate. The class 100 LAF hood is designed to protect the critical area from airborne particles through filtration and airflow. A difference in viable particulate matter at the two sites was observed using the air sampler; however, no CFUs were found within either LAF hood. Another important factor in the contamination potential of the environment is the personnel within the environment. The human body can shed approximately 10,000 CFUs/ min. 22 This not only affects the microbial load of the air surrounding the human, but provides a source for contamination by touch. Cleanroom garb (e.g., scrubs, gown) is designed to reduce the amount of personnel shedding that occurs within the environment; however, a plastic gown reduces total shedding by only 60%. 22 Gloves are designed to reduce the likelihood of shedding and touch contamination from microbial flora residing on the skin. Since there was no significant difference in the quality of the final products prepared in the cleanroom and traditional practice sites, any environmental considerations are overshadowed by the importance of the operator s aseptic technique. The Food and Drug Administration, USP, and professional pharmacy associations have stressed the need for effective quality assurance programs for sterile product compounding. They have also emphasized the use of a controlled environment, such as that provided by cleanroom technology, when preparing sterile admixtures, despite the lack of evidence to suggest that these controlled environments independently improve product quality. It cannot be assumed that the cleanroom environment and garb will prevent or reduce contamination. This false assumption could breed indifference in the personnel working within cleanrooms, thereby weakening their adherence to aseptic technique. This study demonstrates that when admixtures are prepared within a class 100 LAF hood, the operator becomes the most important variable affecting microbial contamination. It is dangerous to assume that the use of a cleanroom will independently improve the quality of patient care by eliminating contamination. Once a baseline environmental quality (class 100 LAF hood) is established, admixture quality assurance efforts should focus on other critical factors. Continuous quality assurance of personnel s aseptic technique, including effective monitoring and training for the personnel preparing admixtures, is paramount. The use of media-fill runs to validate personnel, processes, and equipment (e.g., automatic compounding devices or pumps) also en- Am J Health-Syst Pharm Vol 62 v 15,
7 sures the quality of sterile products. Finally, the proper functioning of LAF hoods should be established. Limitations. There are limitations to this study. Only one growth medium was used in this study. TSB is an ideal medium for supporting the growth of aerobic gram-positive and -negative bacteria and fungi. Contamination could occur from sources that do not thrive on TSB, such as anaerobes. Growth media to support anaerobes were not used in order to preserve the study s large sample size. The significance of this study is relative only to the locations in which it was performed. practice settings vary widely from pharmacy to pharmacy, although many have a class 100 LAF hood. Cleanrooms also vary, but to a far lesser extent. Different results may have been seen if different locations were used. Arguments could be made that the two investigators may have introduced bias. However, this is unsubstantiated, as the results of the study show no statistically significant difference in contamination rates for either investigator in either environment. Conclusion The most important variable affecting microbial contamination of admixtures was the aseptic technique of personnel, not the environment in which the drugs were compounded. a Remel Laboratories, Lenexa, KS, lot References 1. Santell JP, Kamalich RF. National survey of quality assurance activities for pharmacy-prepared sterile products in hospitals and home infusion facilities Am J Health-Syst Pharm. 1996; 53: Morris AM, Schneider PJ, Pedersen CA et al. National survey of quality assurance activities for pharmacy compounded sterile preparations. Am J Health-Syst Pharm. 2003; 60: Pharmaceutical compounding sterile preparations (general information chapter 797). In: The United States pharmacopeia, 27th rev., and The national formulary, 22nd ed. Rockville, MD: The United States Pharmacopeial Convention, 2004: Brier KL, Latiolais CJ, Schneider PJ et al. Effect of laminar air flow and cleanroom dress on contamination rates of intravenous admixture. Am J Hosp Pharm. 1981; 38: Poretz DM, Guynn JB, Duma RJ et al. Microbial contamination of glass bottle (open-vented) and plastic bag (closednonvented) intravenous fluid delivery systems. Am J Hosp Pharm. 1974; 31: Sanders LH, Mabadeje SA, Avis KE et al. Evaluation of compounding accuracy and aseptic techniques for intravenous admixtures. Am J Hosp Pharm. 1978; 35: Ezell JR, Godwin HN, Hassanein RN et al. Comparison of videocassette and personal instruction methods for training pharmacy personnel in aseptic technique. Am J Hosp Pharm. 1988; 45: Mitrano FP, Baptista RJ, Newton DW et al. Microbial contamination potential of solutions in prefilled disposable syringes used with a syringe pump. Am J Hosp Pharm. 1986; 43: Dirks I, Smith FM, Furtado D et al. Method for testing aseptic technique of intravenous admixture personnel. Am J Hosp Pharm. 1982; 39: Morris BG, Avis KE, Bowles GC. Quality control plan for intravenous admixture programs. II: validation of operator technique. Am J Hosp Pharm. 1980; 37: Allinson RR, Stach PE, Sherrin TP et al. Compounding times and contamination rates associated with the preparation of intravenous admixtures in three types of plastic containers. Am J Hosp Pharm. 1979; 36: Buth JA, Coberly RW, Eckel FM. A practical method of sterility monitoring of IV admixtures and a method of implementing a routine sterility monitoring program. Drug Intell Clin Pharm. 1973; 7: Dees EN, Natsios GA. Contamination of intravenous fluids by bacteria and fungi during preparation and administration. Am J Hosp Pharm. 1971; 28: Ravin R, Bahr J, Luscomb F et al. Program for bacterial surveillance of intravenous admixtures. Am J Hosp Pharm. 1974; 31: Hanson AL, Shelley RM. Monitoring contamination levels of in-use intravenous solutions using total sample techniques. Am J Hosp Pharm. 1974; 31: Arnold TR, Hepler CD. Bacterial contamination of intravenous fluids opened in unsterile air. Am J Hosp Pharm. 1971; 28: Miller WA, Smith GL, Latiolais CJ. A comparative evaluation of compounding costs and contamination rates of intravenous admixture systems. Drug Intell Clin Pharm. 1971; 5: Trissel LA, Ogundele AB, Ingram DS et al. Using medium-fill simulation to establish a benchmark microbiological contamination rate for low-risk-level compounding. Am J Health-Syst Pharm. 2003; 60: Trissel LA, Gentempo RW, Anderson RW et al. Using a medium-fill simulation to evaluate the microbial contamination rate for USP medium-risk-level compounding. Am J Health-Syst Pharm. 2005; 62: Crawford SY, Narducci WA, Augustine SC. National survey of quality assurance activities for pharmacy-prepared sterile products in hospitals. Am J Hosp Pharm. 1991; 48: Center for Drugs and Biologics and Office of Regulatory Affairs. Guideline on sterile drug products produced by aseptic processing. Rockville, MD: Food and Drug Administration; 1987 Jun. 22. Vanjare D. New concepts in parenteral manufacturing. PharmaTimes. 1989; 21: Am J Health-Syst Pharm Vol 62 v 15, 2005
ENVIRONMENTAL MONITORING
ENVIRONMENTAL MONITORING Assessment and verification of the adequacy of the aseptic compounding environment is essential. Environmental monitoring programs are designed to promptly identify potential sources
Understanding USP 797
DDK Scientific, Corp. Raul Duarte June 2008 Copyright DDK Scientific, Corp. 2008, 2009 DDK Scientific, Corp. Proprietary The purpose of USP 797 is to prevent harm and fatality to patients that could result
Hand and Glove Hygiene Keys to Safe Compounding
Page 1 of 5 print this article Clinical ISSUE: MARCH 2012 VOLUME: 39 Hand and Glove Hygiene Keys to Safe Compounding by Steve Frandzel New Orleans Improper hand hygiene is a common factor in the spread
Recommendations for the Safe Use of Handling of Cytotoxic Drugs
Recommendations for the Safe Use of Handling of Cytotoxic Drugs Introduction Cytotoxic drugs are toxic compounds and are known to have carcinogenic, mutagenic and/or teratogenic potential. With direct
Everything you want to know about USP 797
Everything you want to know about USP 797 Dr. Linda D. Lee Director of Operations Waste Management Healthcare Solutions September. 22, 2009 Goals High level understanding of USP 797 Who does it apply too
Environmental Monitoring
Environmental Monitoring Purpose of Environmental Monitoring Critical process within the pharmaceutical and biotechnology industries. Determines the microbial and particulate content of cleanroom air and
COMPOUNDING PHARMACY IN THE HOSPITAL SETTING SATURDAY/11:30AM-12:30PM
HOSPITAL FOCUS: COMPOUNDING PHARMACY IN THE HOSPITAL SETTING SATURDAY/11:30AM-12:30PM ACPE UAN: 0107-9999-16-034-L04-T 0.1 CEU/1 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacy Technicians:
Sample Pharmacy CLEANING AND SANITIZING PROCEDURE P-304.1
P-304.1 1.0 Definition and Purpose: To standardize and define the process by which the controlled Cleanroom environments (ISO Class 5, 7, and 8) and the general pharmacy prep area is cleaned, disinfected,
Environmental Monitoring of Clean Rooms
Environmental Monitoring of Raul Duarte President DDK Scientific, Corp. Copyright DDK Scientific, Corp. 2008, 2009, DDK Scientific, Corp. Proprietary A manufacturing facility for pharmaceutical products
Hazardous Drug. Cleanroom. Standards
Hazardous Drug Cleanroom Standards Module 3 Table of Contents Section A... 1 A.1 International Standards Organization (ISO) Classifications... 1 A.2 Hazardous Drug Cleanroom and Anteroom... 1 A.2.1 Location
USP <797> Cleanroom Design and Environmental Monitoring. Andrew King, USP <797> Specialist CETA Member RCCP-SC
USP Cleanroom Design and Environmental Monitoring Andrew King, USP Specialist CETA Member RCCP-SC Objectives The objectives of this presentation: To summarize basic cleanroom concepts and how
Environmental Monitoring
Chapter 10 Environmental Monitoring By the end of this chapter, you will be able to: l List the types of environmental testing l Name three types of checks that are carried out to ensure the isolator is
EDUCATOR S LESSON PLAN
EDUCATOR S LESSON PLAN Pharmacy Technician Training Program Student Version Orientation Orientation introduces the student to basic terms and definitions. An introduction to the Pharmacy Technician Certification
GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS
GUIDELINES FOR NUCLEAR PHARMACY TECHNICIAN TRAINING PROGRAMS Prepared by Ad Hoc Committee on Nuclear Pharmacy Technicians Nuclear Pharmacy Section Academy of Pharmacy Practice and Management American Pharmaceutical
AMENDED January 27, 2015
Proposed Language To Amend 1735 in Article 4.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows: 1735. Compounding in Licensed Pharmacies. (a) Compounding means any of
This course was written for RN.ORG by an outside consultant and RN.ORG has rights for distribution but is not responsible for the contents.
Safe Handling of Hazardous Drugs WWW.RN.ORG Reviewed September, 2015, Expires September, 2017 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2015 RN.ORG,
BRIEFING 797 Pharmaceutical Compounding Sterile Preparations,
BRIEFING 797 Pharmaceutical Compounding Sterile Preparations, USP 39 page 626. It is proposed to revise this chapter to improve clarity, respond to stakeholder input, and reflect new science. Major edits
USP Chapter <797> Update on Recent Revisions
USP Chapter Update on Recent Revisions Claudia C. Okeke, Ph.D., R.Ph. Scientific Fellow United States Pharmacopeia NABP Annual Meeting Tuesday, May 20, 2008 Members of the SCC Committee Chair - David
Cleaning. By the end of this chapter, you will be able to: Introduction. Definitions. Chapter 9
Chapter 9 By the end of this chapter, you will be able to: l Define the terms cleaning, decontamination, disinfection l List the factors that affect disinfection l Describe the aims of a cleaning schedule
Safe Handling of Cytotoxic Materials
Safe Handling of Cytotoxic Materials Kara Henman RN, MN, CON(C) Oncology Practice Consultant Cancer Care Nova Scotia What are hazardous drugs? Chemotherapy Immunosuppressive agents Biological agents Antiviral
Infection Control Checklist
CHAPTER 9 Infection Control Checklist The Joint Commission, in its prevention and control of infection (IC) standards, requires organizations to take precautions to reduce the risk of acquiring and transmitting
Aseptic preparations, including TPN, for a limited number of patients
Aseptic preparations, including TPN, for a limited number of patients Group F (TPN) 1 Objective Presentation of our business case: setting up an aseptic TPN production in the Hilton Pharmacy instead of
CHAPTER 17 STERILE PRODUCT COMPOUNDING 17-1
CHAPTER 17 STERILE PRODUCT COMPOUNDING 17-1 Sterile Product Compounding Reference: 1) United States Pharmacopeia chapter 797 (USP) 2) CMS: 482.25(b)(1) - All compounding, packaging, and dispensing
Bill Mixon, RPh, MS Senior Associate Gates Healthcare Associates
Bill Mixon, RPh, MS Senior Associate Gates Healthcare Associates 14 pharmacists and 1 epidemiologist make up the committee USP staff FDA and CDC representatives have input but do not vote Call for Candidates
Cleanroom. For. Sterile Manufacturing Facilities
Cleanroom For Sterile Manufacturing Facilities Praphon Angtrakool Food and Drug Administration 1 WHO TRS No. 823 Annex 1, 1992 (1) General 17.1 The production of sterile preparations should be carried
FDA and the Compounding Pharmacy
FDA and the Compounding Pharmacy Scott Sutton, Ph.D. [email protected] 41 Overview of Presentation The Recent Events GCP and GMP Basics the 483 Review H.R. 3204 Outsourcing Facility Preparation
CLEAN ROOM MONITORING REGULATORY STANDARDS
CLEAN ROOM MONITORING REGULATORY STANDARDS Air Classification as per Schedule M Maximum permitted number of particles / m3 equal or above at rest in operation 0.5µm 5.0µm 0.5µm 5.0µm A 3,520 29 3,500 29
Curriculum Vitae. Luci A. Power. Education: M.S. Hospital Pharmacy, 1977 Northeastern University, Boston, Massachusetts
Curriculum Vitae Luci A. Power Education: M.S. Hospital Pharmacy, 1977 Northeastern University, Boston, Massachusetts Licensure: California, 1978 Experience: B.S. Pharmacy, 1969 Northeastern University,
Qualification of an Environmental Monitoring Program
[ Scott Sutton Qualification of an Environmental Monitoring Program Scott Sutton Microbiology Topics discusses various topics in microbiology of practical use in validation and compliance. We intend this
Hospital Pharmacy Automation: Drug Storage and Retrieval
WHITE PAPER USP CHAPTER 797 CLEAN ROOM APPLICATION Hospital Pharmacy Automation: Drug Storage and Retrieval The technical information regarding USP Chapter (797) and the performance of the Swisslog device
Manufacturing. Environmental Monitoring Particle Counts Are Easy B IOP ROCESSTECHNICAL. Scott E. Mackler
B IOP ROCESSTECHNICAL Environmental Monitoring Particle Counts Are Easy Scott E. Mackler Manufacturing pharmaceutical and biotechnology products requires that the appropriate level of quality be designed
How single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs
WHITE PAPER 7004 How single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs By John Boehm Business Unit Manager Colder Products Company Today s
Open Microphone Meeting:
Open Microphone Meeting: USP General Chapter Pharmaceutical Compounding Sterile Preparations October 21, 2015 2:00 p.m. to 4:00 p.m. EDT Agenda Welcome Overview of USP s Revision Process Overview
INFECTION CONTROL PRECAUTIONS
INFECTION CONTROL PRECAUTIONS Outline Standard Precautions Droplet Precautions Contact Precautions Airborne Precautions References STANDARD PRECAUTIONS Use Standard Precautions, or the equivalent, for
patient safety A commitment to GE Healthcare
GE Healthcare A commitment to patient safety GE Healthcare is committed to providing radiopharmaceuticals that are compounded and dispensed accurately. Quality assurance and patient safety are the cornerstones
Rules for Compounded Sterile Preparations (CSPs)
Introduction: Despite the attention in this document to describe the provision, maintenance, and evaluation of air quality, the avoidance of direct or physical contact contamination is paramount. Since
The Microbial Bioburden of USP 797 Compliance. Simplifying Environmental Quality and Control Practices for Pharmaceutical Compounding
The Microbial Bioburden of USP 797 Compliance Simplifying Environmental Quality and Control Practices for Pharmaceutical Compounding PathCon Laboratories Fall 2009 Table of Contents Introduction a primer
4729-16-11 Hazardous Drugs Compounded by a Prescriber.
ACTION: Original DATE: 11/30/2015 8:57 AM 4729-16-11 Hazardous Drugs Compounded by a Prescriber. (A) A facility where a prescriber is compounding or handling hazardous drugs shall be licensed as a terminal
Traffic Patterns in the OR: Has it Become a Super Highway?
Traffic Patterns in the OR: Has it Become a Super Highway? Joan Blanchard RN BSN MSS CNOR CIC Movement of patients and personnel Signage Design of the perioperative suite Unrestricted Area Semi-restricted
Risk-Based Environmental Monitoring. Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI
Risk-Based Environmental Monitoring Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI Presenter Marsha Stabler Hardiman Over 20 years experience in the
By Lawrence A. Trissel, B.S., R.Ph., FASHP. Modified from the original presentation March 9, 2006
USP Chapter : Beyond Use Dating, Stability, and Storage Modified from the original presentation March 9, 2006 By Lawrence A. Trissel, B.S., R.Ph., FASHP Supported by an unrestricted educational grant
Raleigh, NC May 12 th & 13 th 2016. Meeting The New ISO Cleanroom Standards And Changing EU Guidance How Will You Comply?
Raleigh, NC May 12 th & 13 th 2016 Meeting The New ISO Cleanroom Standards And Changing EU Guidance How Will You Comply? The International Cleanroom Standards (ISO 14644-1 & 2) have been updated, these
Via email [email protected]
1/23/15 Ms. Allison Benz, R.Ph., M.S. Director of Professional Services Texas State Board of Pharmacy William P. Hobby Building 333 Guadalupe Street, Suite 3-600 Austin, Texas 78701 Via facsimile transmission:
5:00 GUIDELINES FOR ORDERING, PREPARATION, DISPENSING, HANDLING, AND DISPOSAL OF
5:00 GUIDELINES FOR ORDERING, PREPARATION, DISPENSING, HANDLING AND DISPOSAL OF INTRAVENOUS AND HAZARDOUS DRUGS 5:01 Goals 5:02 Definitions 5:03 Hazardous Medication List 5:04 Personnel Requirements, Training
Safe IV Compounding Procedures: The Release of ISMP Guidelines
Safe IV Compounding Procedures: The Release of ISMP Guidelines Matthew P. Fricker, Jr., MS, RPh, FASHP, Program Director Institute for Safe Medication Practices 1 Objectives List system based causes of
Validating and Monitoring the Cleanroom
6 Validating and Monitoring the Cleanroom Kevina O Donoghue Overview... 6-1 Cleanroom Design... 6-1 Principles of Cleanroom Validation and Testing... 6-2 Cleanroom Validation... 6-2 So How Does One Determine
USP <797> A Road to Compliance The New Mexico Board of Pharmacy
USP A Road to Compliance The New Mexico Board of Pharmacy What is the USP? The United States Pharmacopeia and The National Formulary (USP-NF) is a compilation of drug monographs, biologics, medical
Guidance for Industry
Guidance for Industry Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products For questions on the content of the guidance,
Promoting safer use of injectable medicines
Promoting safer use of injectable medicines A template standard operating procedure for: prescribing, preparing and administering injectable medicines in clinical areas Introduction The use of injectable
Regulations Concerning
Regulations Concerning Airborne Particle Counting Two types of activities performed with an airborne particle counter: Classification focuses primarily on the environment Particle Counting Applications
Short Report: Failure of Burkholderia pseudomallei to Grow in an Automated Blood Culture System
Accepted for Publication, Published online October 13, 2014; doi:10.4269/ajtmh.14-0018. The latest version is at http://ajtmh.org/cgi/doi/10.4269/ajtmh.14-0018 In order to provide our readers with timely
DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Guidance for Industry Current Good Manufacturing Practice Interim Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act DRAFT GUIDANCE This guidance document is
Chemotherapy Spill Response:
Chemotherapy Spill Response: Antineoplastic Spills Outside Of A Fume Hood Lisa Hudley, RN Training Coordinator Safety & Environmental Compliance William Guess Director Safety & Environmental Compliance
The use of risk assessment tools for microbiological assessment of cleanroom environments. by Tim Sandle
The use of risk assessment tools for microbiological assessment of cleanroom environments by Tim Sandle Email: [email protected] / [email protected] Web: www.pharmig.blogspot.com Environmental
ASHP Guidelines on Compounding Sterile Preparations
Drug Distribution and Control: Preparation and Handling Guidelines 75 ASHP Guidelines on Compounding Sterile Preparations Purpose The compounding of medications is a fundamental part of pharmacy practice.
CLASSIFICATION OF CLEANROOMS
CLASSIFICATION OF CLEANROOMS Cleanrooms are classified by the cleanliness of their air. The method most easily understood and most universally applied is the one suggested in the earlier versions (A to
Quantifying Bacterial Concentration using a Calibrated Growth Curve
BTEC 4200 Lab 2. Quantifying Bacterial Concentration using a Calibrated Growth Curve Background and References Bacterial concentration can be measured by several methods, all of which you have studied
Draft guidance for registered pharmacies preparing unlicensed medicines
Draft guidance for registered pharmacies preparing unlicensed medicines January 2014 1 The General Pharmaceutical Council is the regulator for pharmacists, pharmacy technicians and registered pharmacies
REGULATION 3 PHARMACY TECHNICIANS
REGULATION 3 PHARMACY TECHNICIANS 03-00 PHARMACY TECHNICIANS REGISTRATION/PERMIT REQUIRED 03-00-0001 DEFINITIONS (a) Pharmacy technician means those individuals, exclusive of pharmacy interns, who assist
Hazardous Drugs Spill Kit
Hazardous Drugs Spill Kit About the Joint Venture Baxter Pharmacy Services and CRG Healthcare have come together to produce the Hazardous Drugs Spill Kit Baxter Pharmacy Services Provides aseptically prepared
INSTITUTIONAL POLICY AND PROCEDURE (IPP) Department: Manual: Section:
HOSPITAL NAME INSTITUTIONAL POLICY AND PROCEDURE (IPP) Department: Manual: Section: TITLE/DESCRIPTION POLICY NUMBER HANDLING OF H AZARDOUS DRUGS EFFECTIVE DATE REVIEW DUE REPLACES NUMBER NO. OF PAGES APPROVED
3039878000or8009926372
3039878000or8009926372 bi s a l e s @me s a l a bs. c om Regulatory officials and sterilization experts have voiced concerns regarding the appropriateness of using a Biological Indicator (BI) Ampoule interchangeably
Basic Requirements For Aseptic Manufacturing Of Sterile Medicinal Products A Comparison Between Europe And USA
Basic Requirements For Aseptic Manufacturing Of Sterile Medicinal Products A Comparison Between Europe And USA Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory Affairs
Lab Exercise 3: Media, incubation, and aseptic technique
Lab Exercise 3: Media, incubation, and aseptic technique Objectives 1. Compare the different types of media. 2. Describe the different formats of media, plate, tube etc. 3. Explain how to sterilize it,
Pharmacy Technician A. Interpersonal Skills Physical Effort Concentration Complexity
Job Class Profile: Pharmacy Technician A Pay Level: CG-28 Point Band: 578-621 Accountability & Decision Making Development and Leadership Environmental Working Conditions Factor Knowledge Interpersonal
Test Method for the Continuous Reduction of Bacterial Contamination on Copper Alloy Surfaces
Test Method for the Continuous Reduction of Bacterial Contamination on Copper Alloy Surfaces Test Organisms: Staphylococcus aureus (ATCC 6538) Enterobacter aerogenes (ATCC 13048) Pseudomonas aeruginosa
7 Deadly Myths of USP 797 Webinar Q&A By Eric Kastango
7 Deadly Myths of USP 797 Webinar Q&A By Eric Kastango Q: Should gowns that tie in back be used in a clean room? A: The chapter states: a non-shedding gown with sleeves that fit snugly around the wrists
USP <797> Introduction
Pharmaceutical Compounding Sterile Preparations Summary (Added by MS) This document summarizes the current version of USP , specifically as it pertains to environmental conditions, worker and
Equipment and Facilities
6 Equipment and Facilities LEARNING OBJECTIVES 1. Discuss USP 797 guidelines and their importance in preventing microbial contamination. 2. Discuss requirements for the intravenous area according to USP
The Perfect Partnership for GMP Cleaning Services. Total Cleaning Solutions from Micronclean & Isocleanse
The Perfect Partnership for GMP Cleaning Services Total Cleaning Solutions from Micronclean & Isocleanse 02 03 The Micronclean Offer Micronclean have offered a specialist ISO Class 4/GMP Grade B cleanroom
Effective Heat Sterilization in CO 2 Incubators
Effective Heat Sterilization in CO 2 Incubators Volume 4, Number 3 Key Words Key Words Class 100 air Contamination control Contamination elimination HEPA filtration Incubator Heat Sterilization White Paper
Hand Hygiene and Infection Control
C Hand Hygiene and Infection Control Sirius Business Services Ltd www.siriusbusinessservices.co.uk Tel 01305 769969 [email protected] Whatever your First Aid, Fire Safety or Health & Safety
International Standard ISO 14644
International Standard ISO 14644 Cleanrooms and associated controlled environments Praphon Angtrakool Food and Drug Administration 1 International Standard : ISO 14644 ISO 14644 consists of the following
Safe Handling of Hazardous Drugs
Safe Handling of Hazardous Drugs Module 1 Includes Recommended Procedures and Techniques Table of Contents Section A... 1 A.1 Potential Hazards of Handling Cytotoxic/Hazardous Drugs... 1 A.2 Hazardous
Prevention and control of infection in care homes. Summary for staff
Prevention and control of infection in care homes Summary for staff 1 DH INFORMATION READER BOX Policy Clinical Estates HR / Workforce Commissioner Development IM & T Management Provider Development Finance
NORTH CAROLINA BOARD OF NURSING NURSE AIDE II TRAINING MODULE
PART A: PREPARING FOR ADMINISTRATION OF IV FLUIDS All four parts of this module, including skills checklists must be successfully completed in order to complete this training module. This activity is a
1-800-862-2731 Administration of Meropenem For Child
1 Drug Name: _Meropenem 1-800-862-2731 Administration of Meropenem For Child Dosage: milligrams every hours over 5 minutes Key Points: FLUSHING: Meropenem Heparin flush 1. Always wash your hands with an
Planning Issues for Hospital Pharmacies with Growing Outpatient Populations
Planning Issues for Hospital Pharmacies with Growing Outpatient Populations In recent years, there has been an increasing emphasis in healthcare on the provision of ambulatory care services. It is predicted
Microbiological Evaluation of the STI Series 2000 Medical Waste Treatment Process
WNWN International,Inc. WNWN International Phone: 860-675-1217 Fax 860-675-1311 PO Box 1164 Burlington, CT. 06013 USA Microbiological Evaluation of the STI Series 2000 Medical Waste Treatment Process January
Health Canada Manufacturing and Compounding Drug Products in Canada: A Policy Framework Guidelines for P.E.I. Community and Hospital Pharmacists
Health Canada Manufacturing and Compounding Drug Products in Canada: A Policy Framework Guidelines for P.E.I. Community and Hospital Pharmacists October 2001 In response to pharmacists questions about
Introduction. Contamination sources
Introduction Tim Sandle www.pharmamicro.com Cleanrooms and environmental monitoring Contamination sources Contamination control The human microbiome and the microbial ecology of people Case study: Microorganisms
ENVIRONMENTAL TESTING & MONITORING: Deciphering Compliance Requirements for Pharmaceutical and Medical Device Manufacturers A WHITE PAPER
A WHITE PAPER ENVIRONMENTAL TESTING & MONITORING: Deciphering Compliance Requirements for Pharmaceutical and Medical Device Manufacturers By Scott Mackin A WHITE PAPER ENVIRONMENTAL TESTING & MONITORING:
GMP ANNEX 1 REVISION 2008, INTERPRETATION OF MOST IMPORTANT CHANGES FOR THE MANUFACTURE OF STERILE MEDICINAL PRODUCTS
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 032-2 8 January 2010 RECOMMENDATION GMP ANNEX 1 REVISION 2008, INTERPRETATION OF MOST IMPORTANT CHANGES FOR THE MANUFACTURE
Chemotherapy: Safety Protocols. Janet Modrakovic, BAS, CVT
Chemotherapy: Safety Protocols Janet Modrakovic, BAS, CVT The word chemotherapy strikes fear in the heart of every pet owner whose beloved pet has been diagnosed with cancer. The incidence of cancer in
Standardization of Technician Education Want it? Need it? Janet Teeters, M.S., R.Ph. Director of Accreditation Services ASHP
Standardization of Technician Education Want it? Need it? Janet Teeters, M.S., R.Ph. Director of Accreditation Services ASHP Disclosure Director of Accreditation Services Standardized Technician Education
National Patient Safety Agency. Risk Assessment of Injectable Medicines. STEP 1 Local Risk Factor Assessment. STEP 2 Product Risk Factor Assessment
NPSA Injectable Medicines Risk Assessment Tool National Patient Safety Agency Risk Assessment of Injectable Medicines STEP 1 Local Risk Factor Assessment. Carry out a baseline assessment in a near patient
Biosafety Spill Response Guide
Yale University Office of Environmental Health & Safety Biosafety Spill Response Guide Office of Environmental Health & Safety 135 College Street, 1 st Floor, New Haven, CT 06510 Telephone: 203-785-3550
CONNECTICUT. Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION
CONNECTICUT Downloaded January 2011 19 13 D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION (d) General Conditions. (6) All medications shall be administered only by licensed
Barrier and isolation systems
VOLUME 21, NO. 04, APRIL 2007 T H E M A G A Z I N E O F C O N T A M I N A T I O N C O N T R O L T E C H N O L O G Y Barrier and isolation systems INTERPHEX 2007 Showguide Ventilation and exhaust systems
Cleaning validation of cleanrooms and preparation equipments
Cleaning validation of cleanrooms and preparation equipments Head of production Central Pharmacy, Geneva University Hospitals EAHP Foundation Seminar: Patient Safety; More About Compounding" 23-25 May,
Bloodborne Pathogens Program Revised July, 5 2012
Bloodborne Pathogens Program Revised July, 5 2012 Page 1 of 16 Table of Contents 1.0 INTRODUCTION...3 1.1 Purpose...3 1.2 Policy.3 2.0 EXPOSURE CONTROL METHODS 4 2.1 Universal Precautions.4 2.2 Engineering
Environmental Monitoring Risk Assessment
Environmental Monitoring Risk Assessment By Tim Sandle INTRODUCTION Environmental Monitoring describes the microbiological testing undertaken in order to detect changing trends of microbial counts and
